Myriad Genetics
MYGN
281 hedge funds and large institutions have $3.74B invested in Myriad Genetics in 2014 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 67 increasing their positions, 132 reducing their positions, and 46 closing their positions.
250% more funds holding in top 10
Funds holding in top 10: 2 → 7 (+5)
69% more capital invested
Capital invested by funds: $2.21B → $3.74B (+$1.53B)
28% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 46
4% more funds holding
Funds holding: 271 → 281 (+10)
49% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 132
57% less call options, than puts
Call options by funds: $74.4M | Put options by funds: $174M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$128M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$99M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$79.6M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$54M |
| 5 |
SCM
Scopia Capital Management
New York
|
+$48.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCG
Luxor Capital Group
New York
|
-$45.9M |
| 2 |
RA
Royce & Associates
New York
|
-$43.6M |
| 3 |
MCM
Munder Capital Management
Birmingham,
Michigan
|
-$30.2M |
| 4 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
-$23.5M |
| 5 |
RRAM
River Road Asset Management
Louisville,
Kentucky
|
-$23.1M |
MYGN Hedge Fund Activity: Q1 2014 in Review
281 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2014, worth a combined $3.74B — up 69% from $2.21B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new MYGN positions and 46 closed out — a net gain of 13 holders — while 67 added to existing stakes and 132 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $128M. The largest seller was Luxor Capital Group, cutting an estimated $45.9M.
- 281 institutional investors held Myriad Genetics (MYGN) as of Q1 2014, up from 271 in Q4 2013.
- Funds reported $3.74B of Myriad Genetics stock for Q1 2014, up 69% quarter-over-quarter.
- 59 funds opened new Myriad Genetics positions in Q1 2014 and 46 closed out, a net change of +13 holders.
- The largest Myriad Genetics buyer in Q1 2014 was Baillie Gifford & Co, an estimated $128M added.
- The largest Myriad Genetics seller in Q1 2014 was Luxor Capital Group, an estimated $45.9M sold.
Based on aggregated 13F filings for Q1 2014.